Helix BioPharma (TSE:HBP),which is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.
It is now screening patients for the 15th dose level cohort in the ongoing study for safety, tolerability and preliminary efficacy L-DOS47 in Poland.
L-DOS47 is currently being evaluated in two clinical studies - Poland and in the US- as a treatment for certain patients with non-small cell lung cancer.
The Trial Steering Committee has completed the safety review of cohort 14 and recommended that Helix begin enrollment of patients into the fifteenth (15) cohort.